Revolade

Active substance

Eltrombopag

Holder

Novartis

Status  

Closed

Indication

patients aged 1 year and above with primary immune thrombocytopenia (ITP) lasting 6 months or longer from diagnosis and who are refractory to other treatments (e.g. corticosteroids, immunoglobulins).

Public documents

Approbation

Information for the patient

Informed consent

Last update

27/07/2021

Last updated on 13/02/2024